Comparison of 99mTc-sestamibi and doxorubicin to monitor inhibition of P-glycoprotein function
2001
Comparing Two Methods to Monitor Cancer Drug Resistance
publication
Evidence: moderate
Author Information
Author(s): Muzzammil T, Moore M J, Hedley D, Ballinger J R
Primary Institution: University of Toronto
Hypothesis
Can radionuclide imaging with sestamibi provide a more sensitive measure of P-glycoprotein function compared to doxorubicin flow cytometry?
Conclusion
Radionuclide imaging with sestamibi is more sensitive than doxorubicin flow cytometry in distinguishing between sensitive and resistant breast cancer cell variants.
Supporting Evidence
- P-glycoprotein overexpression is linked to chemotherapy resistance.
- Radionuclide imaging with sestamibi has shown promise for non-invasive monitoring.
- Sestamibi showed a greater difference in accumulation between sensitive and resistant cells compared to doxorubicin.
Takeaway
This study looked at two ways to see how cancer cells resist treatment, and found that one method works better than the other.
Methodology
The study compared the accumulation of sestamibi and doxorubicin in different breast cancer cell lines under various conditions.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website